SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Cambridge, USA - 16 August 2024. View of Moderna office entrance with logo sign, Biotechnology industry
Earnings
Moderna Posts Fourth-Straight Earnings Drop but the Bleeding Is Slowing
The company reported $200 million in net losses for the third quarter, but an aggressive and highly successful cost-cutting campaign is helping to stem the downward trend.
November 6, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Eli Lilly's world headquarters in Indianapolis
Obesity
Lilly’s Amylin Agonist Headed to Phase III After Eliciting up to 20% Weight Loss
The highest dose of Eli Lilly’s eloralintide led to 20.1% weight loss after 48 weeks in a Phase II trial, exceeding analyst expectations and highlighting a “potentially best in class profile,” according to BMO Capital Markets.
November 6, 2025
 · 
3 min read
 · 
Heather McKenzie
IN PARTNERSHIP WITH PII
Thoughtful Tech: How Removing Technological Burdens Can Improve Clinical Trial Compliance and Patient Experience
In this episode presented by PII, BioSpace’s head of insights discusses how to relieve clinical trial patients of technological burden to improve compliance with guests Oliver Eden and Travis Webb.
November 6, 2025
 · 
1 min read
 · 
BioSpace Insights
AstraZeneca's sign on its office in California
Earnings
AstraZeneca Builds Obesity Pipeline On ‘Medical Aspect,’ Not Aesthetics
In an investor call Thursday, AstraZeneca CEO Pascal Soriot outlined his company’s approach to obesity drug development based on “the medical aspect” of weight loss, including driving down visceral fat.
November 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Poster sketch image artwork photo collage of body language finger showing gesture symbol thumb down dislike dissatisfied minus no opinion.
FDA
FDA’s Top Cancer Regulator Declined CDER Directorship
The search continues for a new leader for the FDA’s Center for Drug Evaluation and Research after George Tidmarsh resigned on Sunday. Deputy Director Mike Davis is in the running, along with Mary Thanh Hai, currently head of the Office of New Drugs.
November 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Judge hiiting tiny man by gavel. Bankruptcy, lawsuit, protest concept. Vector illustration.
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk’s higher bid.
November 6, 2025
 · 
2 min read
 · 
Tristan Manalac
Composite photo collage of two players hold chess board game hobby tactic horse queen championship leisure isolated on painted background.
Obesity
Novo’s Metsera Bid Attracts FTC Scrutiny as Pfizer Matches $10B Offer
Pressure from the FTC and Pfizer is building around Novo Nordisk’s bid to snatch obesity biotech Metsera. The antitrust watchdog has spotted issues with the structure of Novo’s bid, while its New York-based rival has put more money on the table.
November 6, 2025
 · 
3 min read
 · 
Tristan Manalac
Businessman with boulder vector illustration. Stressed mans carry heavy stone in hands overwhelmed with problem or task. Crisis problem of business people, burden, challenge, conquering concept stock illustration
Radiopharmaceuticals
Novartis’ Pluvicto Heavywork Proves Radiopharma Can Succeed
While investment has slowed in radiopharmaceuticals, analysts predict increased interest to come as Novartis shows just how successful radiopharmaceuticals can be.
November 6, 2025
 · 
5 min read
 · 
Annalee Armstrong
Wrecking Ball Shattering The White Wall. 3D Illustration.
Regulatory
‘Chaotic’ HHS Overhaul a Wrecking Ball Toward a Better FDA: Former CIO
The upheaval of the Health and Human Services workforce and leadership leaves much to be desired in terms of delivery, recently retired FDA Chief Information Officer Vid Desai tells BioSpace, but the regulatory agency is evolving to be more open to much needed change.
November 6, 2025
 · 
5 min read
 · 
Jef Akst
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS